A model‐based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs
British Journal of Pharmacology · 2026
DOI: 10.1111/bph.70337 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Pharmacology, 2026. Verfasst von Shen Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C9, Tolbutamide, Flurbiprofen, Fluconazole. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Background The activity of CYP2C9, an important drug metabolism enzyme, is subject to the impact of genetic polymorphism. The single nucleotide polymorphism *3 is significantly associated with the increased exposure of CYP2C9 substrates. In addition, metabolic enzyme inhibitors such as fluconazole may also increase the drug exposure of CYP2C9 substrates. However, the interactions between the impact of CYP2C9 genotypes and the inhibitory effects of interacting drugs with respect to the CYP2C9 mediated fraction of metabolism ( f m ) are rarely investigated. Experimental Approaches Using tolbutamide, flurbiprofen and ketoprofen as representative substrates with high, medium and low CYP2C9 mediated f m , respectively, an open‐label, block‐randomized, crossover clinical drug–drug interaction study was conducted using fluconazole as a representative interacting drug. A pharmacometric model‐based analysis was subsequently performed to assess the impact of CYP2C9 genotypes on the absolute and fractional changes in apparent clearance (CL/F) with fluconazole co‐administration. Key Results Our study shows tolbutamide and flurbiprofen, but not ketoprofen, exhibit CYP2C9 genotype‐dependency on both absolute and fractional changes in CL/F following the fluconazole co‐administration. An interesting finding is the CYP2C9 genotype‐dependency on fluconazole induced fractional CL/F changes is more pronounced in a CYP2C9 substrate with medium CYP2C9 mediated f m , in comparison to a CYP2C9 substrate with high or low CYP2C9 mediated f m . Conclusions and Implications Our study provides quantitative insights into the genotype‐dependent exposure changes of probe drugs with varying CYP2C9 metabolic contributions following the co‐administration of fluconazole, highlighting the role of CYP2C9 metabolic contributions in guiding the precision dosing of CYP2C9 substrates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
- Gilead Sciences, Inc., Foster City, California, USA.
- Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington, USA.
- Tracy Consultants, Huntsville, Alabama, USA.
ORCID-Profile: Shen Cheng, Darcy R Flora
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Cheng, S., Flora, D. R., Jaber, M. M., Rettie, A. E., Brundage, R. C., & Tracy, T. S. (2026). A model‐based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs. British Journal of Pharmacology. https://doi.org/10.1111/bph.70337
Vancouver
Cheng S, Flora DR, Jaber MM, Rettie AE, Brundage RC, Tracy TS. A model‐based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs. British Journal of Pharmacology. 2026. doi:10.1111/bph.70337
BibTeX
@article{Cheng2026,
author = {Cheng, Shen and Flora, Darcy R and Jaber, Mutaz M and Rettie, Allan E and Brundage, Richard C and Tracy, Timothy S},
title = {A model‐based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70337}
}
EUVIMED